Overview

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Taiho Oncology, Inc.
Treatments:
Futibatinib